These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19882368)

  • 1. Mitoxantrone: benefits and risks in multiple sclerosis patients.
    Martinelli V; Radaelli M; Straffi L; Rodegher M; Comi G
    Neurol Sci; 2009 Oct; 30 Suppl 2():S167-70. PubMed ID: 19882368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitoxantrone for multiple sclerosis.
    Martinelli Boneschi F; Vacchi L; Rovaris M; Capra R; Comi G
    Cochrane Database Syst Rev; 2013 May; (5):CD002127. PubMed ID: 23728638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
    Foo EC; Russell M; Lily O; Ford HL
    Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac effects of mitoxanthrone therapy in patients with multiple sclerosis.
    Pastuszak Ż; Tomczykiewicz K; Piusińska-Macoch R; Stępień A
    Kardiol Pol; 2016; 74(4):380-4. PubMed ID: 26412472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of the long term effect of mitoxantrone on neurological disability in patients with active multiple sclerosis].
    Mesaros S; Stojsavljević N; Dujmović I; Mandić E; Drulović J
    Srp Arh Celok Lek; 2004; 132(7-8):209-13. PubMed ID: 15615176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone for multiple sclerosis in clinical practice.
    Rizvi SA; Zwibel H; Fox EJ
    Neurology; 2004 Dec; 63(12 Suppl 6):S25-7. PubMed ID: 15623666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
    van de Wyngaert FA; Beguin C; D'Hooghe MB; Dooms G; Lissoir F; Carton H; Sindic CJ
    Acta Neurol Belg; 2001 Dec; 101(4):210-6. PubMed ID: 11851027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitoxantrone for multiple sclerosis.
    Martinelli Boneschi F; Rovaris M; Capra R; Comi G
    Cochrane Database Syst Rev; 2005 Oct; (4):CD002127. PubMed ID: 16235298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The current role of mitoxantrone in the treatment of multiple sclerosis.
    Cocco E; Marrosu MG
    Expert Rev Neurother; 2014 Jun; 14(6):607-16. PubMed ID: 24834466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.
    Hartung HP; Gonsette R; König N; Kwiecinski H; Guseo A; Morrissey SP; Krapf H; Zwingers T;
    Lancet; 2002 Dec 21-28; 360(9350):2018-25. PubMed ID: 12504397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a new place for mitoxantrone in the treatment of multiple sclerosis?
    Wawrzyniak S; Rzepiński Ł
    Neurol Neurochir Pol; 2020; 54(1):54-61. PubMed ID: 31922582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mitoxantrone].
    Pericot I; Montalban X
    Neurologia; 2003; 18(6):318-23. PubMed ID: 12838451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aggressive multiple sclerosis. Definition and specific therapeutic indication].
    Edan G
    Presse Med; 2004 Feb; 33(3):187-91; discussion 192. PubMed ID: 15029034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?
    Murray TJ
    Expert Opin Drug Saf; 2006 Mar; 5(2):265-74. PubMed ID: 16503747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic role of mitoxantrone in multiple sclerosis.
    Neuhaus O; Kieseier BC; Hartung HP
    Pharmacol Ther; 2006 Jan; 109(1-2):198-209. PubMed ID: 16095713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of mitoxantrone in the treatment of multiple sclerosis.
    Jeffery DR; Herndon R
    Neurology; 2004 Dec; 63(12 Suppl 6):S19-24. PubMed ID: 15623665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
    Pascual AM; Téllez N; Boscá I; Mallada J; Belenguer A; Abellán I; Sempere AP; Fernández P; Magraner MJ; Coret F; Sanz MA; Montalbán X; Casanova B
    Mult Scler; 2009 Nov; 15(11):1303-10. PubMed ID: 19825889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.